Fibroblast growth factor receptor (FGFR) inhibitors (FGFRis) are a potential therapeutic
option for squamous non-small cell lung cancer (Sq-NSCLC). Because appropriate patient …

HNF1B is overexpressed in clear cell epithelial ovarian cancer, and we observed epigenetic
silencing in serous epithelial ovarian cancer, leading us to hypothesize that variation in this …

Genome-wide association studies have identified several risk associations for ovarian
carcinomas but not for mucinous ovarian carcinomas (MOCs). Our analysis of 1,644 MOC …

Ovarian small cell carcinoma of hypercalcemic type – evidence of germline origin and smarca4
gene inactivation. a pilot study Journals Advances in Dermatology and Allergology/Postępy …

The development of targeted therapies for non-small cell lung cancer (NSCLC), such as the
epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase …

Objective DNA repair pathways are potential targets of molecular therapy in cancer patients.
The FANCD2, BRIP1, BRCA1/2, and FANCF genes are involved in homologous …

Background SMARCA4 mutations have recently been identified as driving lesions of the
ovarian small cell carcinoma of hypercalcemic type (SCCHT). Familial occurrence of this …

Considering the vast biological diversity and high mortality rate in high-grade ovarian
cancers, identification of novel biomarkers, enabling precise diagnosis and effective, less …

While fibroblast growth factor receptors (FGFRs) are involved in several biological pathways
and FGFR inhibitors may be useful in the treatment of squamous non-small cell lung cancer …

Purpose The detection of epidermal growth factor receptor (EGFR) mutations in plasma cell-
free DNA (cfDNA) is an auxiliary tool for the molecular diagnosis of non-small cell lung …